By Adriano Marchese
Eupraxia Pharmaceuticals shares rose in premarket trading Tuesday after the company said it received positive data from its eosinophilic esophagitis treatment trials.
Shares traded nearly 6.3% higher in New York at $4.00.
The Toronto and New York-listed biotechnology company said that all three patients that were part of the Resolve phase 1b/2a trial evaluating EP-104GI as a treatment reported reduced symptom severity.
Eosinophilic esophagitis, or EoE, is a chronic immune system disease where a type of white blood cell, called an eosinophil, builds up in the lining of the esophagus and causes averse reactions to certain foods or allergens.
The trial also showed that there was improvement in tissue health among the patients, the largest improvement observed in any of the cohorts to date.
Eupraxia said that these effects are comparable to, or better than, what has been demonstrated by currently approved treatments for EoE.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
February 25, 2025 09:30 ET (14:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。